<DOC>
	<DOCNO>NCT00785577</DOCNO>
	<brief_summary>The purpose study test whether new treatment safe effective treating pain . Patients diabetic peripheral neuropathy include .</brief_summary>
	<brief_title>A Study Treatment Pain Patients With Diabetic Neuropathy .</brief_title>
	<detailed_description />
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Have pain due peripheral neuropathy base disease diagnostic criterion : must Type 1 Type 2 diabetes mellitus , pain must foot , relatively symmetrical onset , daily pain must present least 6 month , diagnosis must confirm score least 3 Part B Michigan Neuropathy Screening Instrument . Have stable glycemic control , glycated hemoglobin ( HbA1c ) less equal 10 % Mean score least 4 24hour average page severity assessment ( daily diary ) Visits 2 3 . Fully complete daily diary least 70 % day Visit 2 3 . Women must test negative serum pregnancy test Visit 1 , must agree use medically acceptable reliable mean birth control determine investigator study 1 month follow last dose study drug . Are competent able freely give informed consent . Have educational level degree understand communicate intelligible investigator study coordinator . Have judge reliable agree keep appointment clinic visit , test , procedure require protocol . Have historical exposure drug know cause neuropathy , history medical condition , include pernicious anemia hypothyroidism , could responsible neuropathy . Have pain clearly differentiated condition interfere assessment diabetic neuropathy pain . Have treatment centrally active neuroleptic drug within 30 day visit 3 . Have intolerance pregabalin frequent and/or severe allergic reaction multiple medication . Have current previous ( within past 1 year ) Axis 1 diagnosis major depressive disorder , mania , bipolar disorder , psychosis , dysthymia , generalize anxiety disorder , alcohol eating disorder accord Diagnostic Statistical Manual Mental Disorders 4th edition ( DSMIV ) criterion , determine investigator confirm MiniInternational Neuropsychiatric Interview ( MINI ) . Have serious unstable cardiovascular , hepatic , renal , respiratory , ophthalmologic , gastrointestinal , hematologic illness , symptomatic peripheral vascular disease , medical condition opinion investigator would compromise participation likely lead hospitalization course study . Have alanine aminotransaminase &gt; 2 time upper limit normal Visit 1 , base reference range central lab . Have prior renal transplant , current renal dialysis , serum creatinine laboratory value &gt; 1.5 time upper limit normal , base reference range central lab Visit 1 . Have diagnosis history glaucoma . Are take excluded medication stop wash prior Visit 2 . Have history substance abuse dependence within past year , exclude nicotine caffeine . Are judge clinically investigator suicidal risk opinion investigator base upon clinical interview Columbia SuicideSeverity Rating Scale . Have positive urine drug screen substance abuse exclude medication . Are unwilling unable comply use data collection device directly record data subject ( daily diary ) . Are pregnant breastfeeding . Are investigator site personnel directly affiliate study and/or immediate family . Are Lilly employee . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Have history recurrent seizure febrile seizure . Have history severe gastroparesis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>